Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Triamcinolone for Acute Pseudophakic CME
NCT02294656Phase 1Completed
- Sponsor
- Soll Eye
- Start
- Nov 2014
- Primary completion
- Sep 2018
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ranibizumab in pseudophakic cystoid macular edema (PCME) (2 arms), sponsored by Soll Eye. Primary endpoints: Incidence and severity of ocular adverse events at 12 months and Incidence and severity of other adverse events at 12 months. Started Nov 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
pseudophakic cystoid macular edema (PCME)
Beyond the preview
Go deeper on NCT02294656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02294656.